Thank you for tuning in to our webinar, Standardizing Immune-Related AE Management in Global Oncology Trials.
As immunotherapies continue to reshape oncology drug development, effectively managing immune-related adverse events (irAEs) has become essential to protecting patient safety, maintaining study continuity, and supporting trial success. Whether you’re designing a new immuno-oncology study or optimizing medical oversight for an ongoing program, our oncology experts are here to help.
Continue the conversation with the speakers from Standardizing Immune-Related AE Management in Global Oncology Trials. Drawing on decades of combined experience in oncology clinical research, medical affairs, and global trial oversight, they partner with sponsors to develop practical strategies for standardized irAE management, cross-functional collaboration, and consistent safety oversight across global studies.
Whether your team is launching a new immunotherapy trial or refining adverse event management processes, we’re here to discuss challenges such as:
- Standardizing immune-related adverse event grading and management
- Strengthening collaboration between sponsors, medical monitors, and investigative sites
- Improving site training and confidence in recognizing and managing irAEs
- Enhancing patient safety while supporting patient retention
- Implementing consistent medical oversight across global oncology trials
Meet The Experts
Gwyn Bebb, MD, PhD
|
Salini Naidu, MD
|
Let’s discuss your study goals and explore practical strategies for improving immune-related adverse event management in your oncology clinical trials. Complete the form to have your questions answered by our experts.